Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

124.03

+0.49 (0.40%)

as of Jul 13, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Jul 13, 2026, 12:00 am

This summary was created by AI, based on 22 opinions in the last 12 months.

Merck & Company (MRK) is regarded as a strong investment opportunity, primarily due to its robust drug pipeline and significant growth potential despite challenges with its blockbuster drug, Keytruda, which is set to go off-patent in 2028. Analysts highlight the company's anticipated increase in sales, particularly from Keytruda and other new drugs in development. While some concerns exist regarding market fluctuations and pricing clarity, a substantial number of experts maintain an optimistic outlook on the stock's performance. With a promising array of drugs poised for release by 2030 and solid financial metrics, including rising cash reserves and share buybacks, MRK is projected to see continued growth, making it a compelling choice for healthcare investors. Expert recommendations suggest a prudent approach to stop-loss levels and target price adjustments.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfeizer, PFE

DON'T BUY

Still relatively inexpensive. They are in restrained growth at this point. Has come off recently because all of the pharmas had a pretty strong year last year and people are shifting into the more resource stocks. It's a defensive stock so there is slower growth.

BUY

Pharma: The trend is really looking quite good. Hasn’t looked at Merck in a while. There was a time when it was 0% return for 10 years. Now, it is in the right sector and it is moving.

PAST TOP PICK

(A TOP PICK Feb 17/11. Up 21.17%.) Still likes but doesn't see as much upside this year.

BUY

An attractive buy. He prefers Abbott Labs (ABT-N), which has growing earnings and is diversified into other products such as medical devices, pharmaceuticals and nutritionals. Terrific dividend. Starting to get attention from value investors.

DON'T BUY

Bit of a poster boy for the whole pharma industry. Something like a leaky boat in that you are rowing and making progress, but constantly bailing. Because of patent expiration, it is very difficult for these companies to create a growth profile.

COMMENT

Has started buying into this sector on the ones that are trading at 10X multiples.

TOP PICK

Model price is $50.75, a 40% upside. Came up 8%-10% in the last couple of weeks, but still has a long ways to go. 4.2% dividend.

TOP PICK

Market was very disappointed in their earnings. Trading at less than 9X earnings. Yield of 4.61%. The model price is $50.15, a 52% upside. It is now all about cost control with these companies. There is huge consolidation in the industry.

WAIT

Recently dropped because they dropped trials of a blood thinner, one of the biggest products in their pipeline. He doesn’t know if this means there will be no sales from this product. He would look seriously at it if it based out at this level. He likes this one and it is reasonable at these levels. He has a small position and is looking to accumulate.

DON'T BUY

Trades at a good multiple but prefers Abbott Labs (ABT-N) because of their pipeline. Growth estimates are only 6%-7% a year.

DON'T BUY

Fine company and reasonably valued but not as cheap as others that he owns. Decent dividend but not anything he would rush into. Still a little uncertainty over the healthcare sector and particularly with this one's pipeline area. Consider Abbott Labs (ABT-N), which has more growth potential.

COMMENT

Took over Schering-Plough in 2009, which expanded their pipeline of pharmaceuticals, drugs, etc. Pays about 4% yield so likes it from an income standpoint. With a 40% payout ratio dividend is relatively safe. Might not give you growth that you would like. If you think economy is going to grind higher, health care is not a sector to be in.

PAST TOP PICK

(A Top Pick Aug 19/09. Up 15.9%.) Merged with Schering-Plough and the combination produced a pipeline that is incomparable in the Pharma sector. Will have sustainable growth for many years to come.

PAST TOP PICK

(A Top Pick May 15/09. Up 46.13%.) (Think this should be Aug 19 and up 12.2%, not May 15 as BNN shows. Bill) Starting to trim out of this one.

DON'T BUY

3rd largest pharmaceutical behind Johnson & Johnson (JNJ-N) and Pfizer (PFE-N). We are in an economic recovery and if this continues and there is no double dip, health-care stocks and consumer staples won't necessarily be your best performers.

Showing 196 to 210 of 305 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)